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Abstract
Backgrounds: The reports of neurological symptoms are increasing in cases with coronavirus disease 2019 (COVID-
19). This multi-center prospective study was conducted to determine the incidence of neurological manifestations
in hospitalized cases with COVID-19 and assess these symptoms as the predictors of severity and death.
Methods: Hospitalized males and females with COVID-19 who aged over 18 years were included in the study. They
were examined by two neurologists at the time of admission. All survived cases were followed for 8 weeks after
discharge and 16 weeks if their symptoms had no improvements.
Results: We included 873 participants. Of eligible cases, 122 individuals (13.97%) died during hospitalization. The
most common non-neurological manifestations were fever (81.1%), cough (76.1%), fatigue (36.1%), and shortness of
breath (27.6%). Aging, male gender, co-morbidity, smoking, hemoptysis, chest tightness, and shortness of breath
were associated with increased odds of severe cases and/or mortality. There were 561 (64.3%) cases with smell and
taste dysfunctions (hyposmia: 58.6%; anosmia: 41.4%; dysguesia: 100%). They were more common among females
(69.7%) and non-smokers (66.7%). Hyposmia/anosmia and dysgeusia were found to be associated with reduced
odds of severe cases and mortality. Myalgia (24.8%), headaches (12.6%), and dizziness (11.9%) were other common
neurological symptoms. Headaches had negative correlation with severity and death due to COVID-19 but myalgia
and dizziness were not associated. The cerebrovascular events (n = 10) and status epilepticus (n = 1) were other
neurological findings. The partial or full recovery of smell and taste dysfunctions was found in 95.2% after 8 weeks
and 97.3% after 16 weeks. The parosmia (30.9%) and phantosmia (9.0%) were also reported during 8 weeks of
follow-up. Five cases with mild headaches and 5 cases with myalgia were reported after 16 weeks of discharge. The
demyelinating myelitis (n = 1) and Guillain-Barré syndrome (n = 1) were also found during follow-up.
Conclusion: Neurological symptoms were found to be prevalent among individuals with COVID-19 disease and
should not be under-estimated during the current pandemic outbreak.
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Introduction
The novel virus from the coronaviridae family termed as
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) was first discovered in December, 2019 after
many pneumonia cases with unknown cause were iden-
tified in Wuhan, China [1]. The SARS-CoV-2 is a β-
coronavirus which is an enveloped virus with helical nu-
cleocapsid and non-segmented positive ribonucleic acid
that can infect mammals [2–5]. The World Health
Organization (WHO) declared coronavirus disease 2019
(COVID-19) as a pandemic outbreak on March 11th,
2020. Over 80 million confirmed cases and about 2 mil-
lion deaths due to COVID-19 were recorded until the
end of 2020 [6].
Several non-respiratory symptoms have been reported
in individuals with COVID-19. The reports of neuro-
logical features are increasing but few large sample-sized
studies reported the incidence of neurological disorders
in people with COVID-19. Myalgia, headaches, and loss
of smell (anosmia) and taste (dysgeusia) sensations are
common neurological findings of the disease [7–9]. Re-
cent studies showed that SARS-CoV-2 could manifest as
life-threatening neurological conditions including ische-
mic stroke, subarachnoid hemorrhage, status epilepticus,
and acute demyelinating encephalomyelitis [10–13].
Neurological symptoms were also reported in epidemic
outbreaks of other coronaviruses including SARS-CoV
and the Middle East respiratory syndrome (MERS)-CoV
[14, 15]. The direct invasion of coronaviruses to the ner-
vous system and over-production of pro-inflammatory
cytokines could be the plausible underlying mechanisms
[16]. This study aimed to determine the incidence of
neurological manifestations in hospitalized cases with
COVID-19 and assess these symptoms as predictors of
severity and death.
Methods
Study design and participants
This was a prospective hospital-based cohort study con-
ducted in Loghman, Imam Hossein, and Imam Kho-
meini hospitals, the three major referral hospitals in
Tehran province, Iran. Males and females aged above 18
years who were diagnosed with COVID-19 based on
WHO recommendations [17] were included in the
study. The sterile nasopharyngeal swabs were inserted in
one nostril of each participant. The collected specimens
were placed into tubes containing viral transport
medium; stored at 4o C to 8o C and were sent to labora-
tories within 12 h. The positive results of real-time
reverse-transcription polymerase chain reaction (RT-
PCR) assay using a SARS-CoV-2 nucleic acid detection
kit (PCR Fluorescence Probing of Sansure Biotech,
Changsha, China) could confirm COVID-19. The exclu-
sion criteria were the presence of other respiratory
infections (e.g. tuberculosis), loss of competence and no
access to surrogates, and withdrawal of consent.
The ethics committee of Shahid Beheshti University of
Medical Sciences approved the study. The protocol was
explained to all participants and if they lacked decision-
making capacity, their legal surrogates were informed
about the study. The printed protocol was also given. It
was explained that participation in the study was op-
tional and the identity information would remain confi-
dential and not published. Written informed consent
was obtained before the initiation of the study.
Data collection
All eligible inpatients were interviewed and the demo-
graphic characteristics including gender, age, smoking
status, and co-morbidities were recorded. Participants
were examined and chest computed tomography (CT)
was performed in all cases. The laboratory tests included
cell blood count, quantitative C-reactive protein (CRP),
lactate dehydrogenase (LDH), and procalcitonin. The se-
verity of COVID-19 was determined using American
Thoracic Society recommendations for community-
acquired pneumonia [18].
To assess neurological manifestations, two neurolo-
gists with at least 5 years of experience took a detailed
history and examined all participants. Any disagreement
was resolved by discussion with each other or consult-
ation with another neurologist. Headaches were known
to be associated with COVID-19 if they fulfilled the cri-
teria for ‘Headache attributed to systemic viral infection’
according to the International Classification of Headache
Disorders [19]. Brain CT and/or magnetic resonance im-
aging (MRI), electroencephalography (EEG), electro-
myography and nerve conduction velocity (EMG-NCV),
as well as cerebrospinal fluid (CSF) analysis were con-
ducted if clinically indicated. Smell and taste dysfunc-
tions were assessed in cases using a self-reporting tool.
The National Institute of Health stroke scale (NIHSS)
was used to evaluate the severity of ischemic stroke. The
NIHSS was designed to objectively quantify neurological
impairments in stroke and consisted of 11 items [20].
Each item can be scored from 0 to 4 and the total pos-
sible scores ranged from 0 to 42. Neurological impair-
ments can be divided into four categories using NIHSS:
a. mild (0–4), b. moderate (5–15), c. Moderate to severe
(16–20), and d. severe (21–42). The intracerebral
hemorrhage (ICH) score was also calculated in partici-
pants with ICH. This is a clinical grading scale using
Glasgow Coma Scale, age, the presence of infratentorial
origin, ICH volume, and the presence of intraventricular
hemorrhage to predict the ICH mortality [21]. The total
score ranged from 0 to 6.
Most included cases were followed for 8 weeks after
discharge from hospital to assess the course of their
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neurological manifestations. If their neurological symp-
toms were persistent, they were followed for further
8 weeks. Cellphone and telephone numbers of each par-
ticipant were recorded and they were interviewed via
phone once per 4 weeks by a neurologist. If cases re-
ported any new-onset neurological complaints, they
would be asked to visit the hospital for further assess-
ments. A phone number was also given to participants
so physical complaints could be reported as soon as pos-
sible. Participants were asked to go to the emergency de-
partment if serious events occurred.
Statistical analysis
Continuous variables were presented as means with
standard deviation (SD) and compared between groups
using independent sample t test. Categorical variables
were described as numbers with percentages and com-
pared between groups using Pearson’s chi-squared test.
To more rigorously assess the predictors of severity and
death due to COVID-19, odds ratio (OR) with 95% con-
fidence interval (CI) was calculated using univariate and
multivariate logistic regression.. The calculated ORs of
neurological manifestations were adjusted for gender,
age, smoking status, and co-morbidity. All analyses were
conducted using the IBM SPSS Software version 25.0
(SPSS Inc., Chicago, IL). Two sided significance testing




The study was initiated on April 7, 2020 when the clin-
ical characteristics of the first hospitalized participant
were assessed. The follow-up of survived cases lasted
until November 18, 2020. Primary screening was per-
formed on 1269 inpatients and 873 cases were included
in the study (Fig. 1). Of eligible participants, 122 individ-
uals died during hospitalization (case fatality rate:
13.97%) and 751 cases were discharged in 11.41 ± 6.20
(mean ± SD) days. There were 62 participants who were
lost to follow-up and 689 individuals completed the
study.
Non-neurological characteristics
The demographic clinical features of included cases dur-
ing hospitalization were presented in Table 1. There
were 551 males (63.7%) and 317 females (36.3%). The
mean ± SD age of participants was 60.71 ± 18.14 years
and 459 individuals (52.6%) aged over 60 years. The
most common non-neurological manifestations were
fever (708/873, 81.1%), cough (664/873, 76.1%), fatigue
(315/873, 36.1%), and shortness of breath (241/873,
Fig. 1 The study diagram
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Table 1 Demographic characteristics and non-neurological clinical manifestations of participants
Clinical features Total Disease severity Death outcome P-




Age (mean ± SD) 60.71 ± 18.14 58.57 ± 17.95 64.82 ± 17.95 0.00 58.12 ± 17.59 76.68 ± 12.46 0.00
≤60 years 414 (47.4) 296 (51.6) 118 (39.5) 400 (53.3) 14 (11.5)
> 60 years 459 (52.6) 278 (48.4) 181 (60.5) 0.00 351 (46.7) 108 (88.5) 0.00
Gender
Female 317 (36.3) 223 (38.9) 94 (31.4) 280 (37.3) 37 (30.3)
Male 556 (63.7) 351 (61.1) 205 (68.6) 0.03 471 (62.7) 85 (69.7) 0.16
Smoking 137 (15.7) 77 (13.4) 60 (20.1) 0.01 101 (13.4) 36 (29.5) 0.00
Co-morbidities 512 (58.6) 318 (55.4) 194 (64.9) 0.01 417 (55.5) 95 (77.9) 0.00
Fever 708 (81.1) 472 (82.2) 236 (78.9) 0.23 614 (81.8) 94 (77.0) 0.21
Cough 664 (76.1) 429 (74.7) 235 (78.6) 0.21 572 (76.2) 92 (75.4) 0.91
Fatigue 315 (36.1) 205 (35.7) 110 (36.8) 0.76 264 (35.2) 51 (41.8) 0.16
Shortness of breath 241 (27.6) 121 (21.1) 120 (40.1) 0.00 154 (20.5) 87 (71.3) 0.00
Sputum production 156 (17.9) 94 (16.4) 62 (20.7) 0.11 133 (17.7) 23 (18.9) 0.80
Chills 101 (11.6) 72 (12.5) 29 (9.7) 0.22 88 (11.7) 13 (10.7) 0.88
Sore throat 97 (11.1) 58 (10.1) 39 (13.0) 0.21 84 (11.2) 13 (10.7) 1.00
Chest tightness 96 (11) 39 (6.8) 57 (19.1) 0.00 70 (9.3) 26 (21.3) 0.00
Nausea 94 (10.8) 64 (11.1) 30 (10.0) 0.65 81 (10.8) 13 (10.7) 1.00
Vomiting 36 (4.1) 26 (4.5) 10 (3.3) 0.48 32 (4.3) 4 (3.3) 0.80
Diarrhea 32 (3.7) 23 (4.0) 9 (3.0) 0.57 28 (3.7) 3 (2.5) 1.00
Hemoptysis 54 (6.2) 20 (3.5) 34 (11.4) 0.00 40 (5.3) 14 (11.5) 0.01
Rhinorrhea 49 (5.6) 26 (4.5) 23 (7.7) 0.06 40 (5.3) 9 (7.4) 0.39
Nasal congestion 24 (2.7) 15 (2.6) 9 (3.0) 0.83 23 (3.1) 1 (0.8) 0.23
Conjunctival congestion 4 (0.5) 2 (0.3) 2 (0.7) 0.61 4 (0.5) 0 (0) 1.00
Categorical variables are presented as numbers (percentages); SD: standard deviation
Table 2 The laboratory data of participants
Laboratory data Total Disease severity Death outcome P-




Leukopenia < 3500/mm3 39 (4.5) 20 (3.5) 19 (6.4) 0.06 30 (4.0) 9 (7.4) 0.09
Leukocytosis > 11,000/mm3 167 (19.1) 108 (18.8) 59 (19.7) 0.79 135 (18) 32 (26.2) 0.03
Neutropenia < 1500/mm3 17 (1.9) 12 (2.1) 5 (1.7) 0.80 14 (1.9) 3 (2.5) 0.72
Neutrophilia > 8000/mm3 291 (33.3) 168 (29.3) 123 (41.1) 0.00 222 (29.6) 69 (56.6) 0.00
Lymphocytopenia < 1000/mm3 434 (49.7) 270 (47.0) 164 (54.8) 0.03 364 (48.5) 70 (57.4) 0.08
Lymphocytosis > 4000/mm3 17 (1.9) 11 (1.9) 6 (2.0) 1.00 15 (2.0) 2 (1.6) 1.00
Thrombocytopenia < 100,000/mm3 65 (7.4) 39 (6.8) 26 (8.7) 0.34 56 (7.5) 9 (7.4) 1.00
Thrombocytosis > 450,000/mm3 11 (1.3) 7 (1.2) 4 (1.3) 1.00 11 (1.5) 0 (0) 0.38
Elevated LDH > 245 U/liter 316 (36.2) 176 (30.7) 140 (46.8) 0.00 217 (28.9) 99 (81.1) 0.00
Elevated CRP > 10 mg/liter 542 (62.1) 339 (59.1) 203 (67.9) 0.01 433 (57.7) 109 (89.3) 0.00
Elevated Procalcitonin > 0.5 ng/ml 63 (7.2) 30 (5.2) 33 (11.0) 0.00 37 (4.9) 26 (21.3) 0.00
Categorical variables are presented as numbers (percentages); LDH lactate dehydrogenase, CRP C-reactive protein
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27.6%). Our analysis showed that aging (severity: OR:
1.020, 95%CI: 1.012 to 1.028; death: OR: 1.08, 95%CI:
1.06 to 1.99), male gender (severity: OR: 1.38, 95%CI:
1.03 to 1.86), presence of co-morbidity (OR: 1.43,
95%CI: 1.11 to 1.98; death: OR: 2.81, 95%CI: 1.79 to
4.42), smoking (severity: OR: 1.62, 95%CI: 1.11 to 2.34;
death: 2.69, 95%CI: 1.73 to 4.18), hemoptysis (severity:
OR: 3.55, 95%CI: 2.01 to 6.28; death: OR: 2.30, 95%CI:
1.21 to 4.36), chest tightness (severity: OR: 3.23, 95%CI:
2.09 to 5.00; death: OR: 2.63, 95%CI: 1.60 to 4.32), and
shortness of breath (severity: OR: 2.51, 95%CI: 1.84 to
3.41; death: OR: 9.61, 95%CI: 6.25 to 14.92) were associ-
ated with increased odds of severity and/or death in
participants.
The most common laboratory abnormalities were ele-
vated CRP (542/873, 61.2%), lymphocytopenia (434/873,
49.7%), elevated LDH (316/873, 35.7%), and neutrophilia
(291/873, 33.3%) (Table 2). The statistical analysis
showed that the elevated procalcitonin (severity: OR:
2.26, 95%CI: 1.35 to 3.78; death: OR: 5.40; 95%CI: 3.12
to 9.34), elevated LDH (severity: OR: 1.99, 95%CI: 1.49
to 2.65; death: OR: 10.63; 95%CI: 6.53 to 17.24), neutro-
philia (severity: OR: 1.68, 95%CI: 1.26 to 2.26; death: OR:
3.10; 95%CI: 2.09 to 4.58), elevated CRP (severity: OR:
1.46, 95%CI: 1.09 to 1.96; death: OR: 6.17; 95%CI: 3.40
to 11.11), leukocytosis (death: OR: 1.62, 95%CI: 1.04 to
2.53), and lymphocytopenia (severity: OR: 1.36, 95%CI:
1.03 to 1.81) were associated with increased odds of se-
verity and/or death due to COVID-19.
Neurological manifestations
Smell and taste dysfunctions were reported in 561
(64.3%) included cases at the time of admission (hypos-
mia: 329/561 or 58.6%; anosmia: 232/561 or 41.4%; dys-
geusia: 561/561 or 100%). They were more common
among females (69.7%) than males (OR: 1.46, 95%CI:
1.08 to 1.96) and also more frequent among non-
smokers (66.7%) than smokers (OR: 1.91, 95%CI: 1.32 to
2.77). Co-morbidities were more frequent among cases
with normal smell and taste sensations (OR: 1.42,
95%CI: 1.07 to 1.89). There were 28 cases with rhinor-
rhea and 17 cases with nasal congestion who reported
loss of smell sensation. Of 561 participants, 142
individuals (25.3%) reported these symptoms as the first
clinical manifestation. Hyposmia/anosmia and dysgeusia
were found to be associated with reduced odds of severe
cases (OR: 0.69, 95%CI: 0.52 to 0.94) and death (OR:
0.63, 95%CI: 0.39 to 0.95) after adjustment for gender,
age, smoking status, co-morbidity, rhinorrhea, and nasal
congestion (Table 3, Fig. 2).
Myalgia (217/873 or 24.9%), headaches (110/873 or
12.6%), and dizziness (104/873 or 11.9%) were other
common neurological symptoms. The incidence rates of
these conditions were not significantly different among
genders. Of 110 individuals with headaches, 71 cases
(64.5%) had migraine-like episodes; 37 participants
(33.6%) had tension-like headaches; and 2 cases (1.9%)
had only cough-related headaches. Headaches had nega-
tive correlation with severity (adjusted OR: 0.52, 95%CI:
0.32 to 0.85) and death due to COVID-19 (adjusted OR:
0.37, 95%CI: 0.75 to 0.92) but myalgia and dizziness
were not associated (Table 3, Fig. 2).
There were 10 cases (1.26%) with COVID-19 who pre-
sented cerebrovascular events (Table 4). The mean age
was 63.40 years (SD: 20.55). Brain CT scans were per-
formed in all cases and ischemic stroke was found in 7
patients (70%) and 3 cases (30%) were diagnosed with
ICH. Of cases with ischemic stroke, mild impairment
was observed in 1 case with NIHSS < 5. We found 3
cases with moderate (NIHSS: 5–15), 1 case with moder-
ate to severe (NIHSS: 16–20), and 2 cases with severe
(NIHSS > 21) neurological impairments. The ICH score
of 4 was calculated in 2 cases and the score of 3 was cal-
culated in 1 patient with ICH. Fever (n = 10), cough (n =
8), fatigue (n = 7), myalgia (n = 3), and headaches (n = 1)
were reported in 10.7 ± 2.91 days prior to cerebrovascu-
lar events but none were severe COVID-19 cases. Six pa-
tients (60%) died in 4.15 ± 2.23 days after hospitalization.
One previously healthy 28 year-old-female was referred
to Loghman hospital with status epilepticus as the sole
clinical manifestation. No history of physical disorders,
head trauma, drug use, or recent respiratory symptoms
was reported from parents. Physical examination re-
vealed bilateral mydriatic and non-reactive pupils with
downward gaze. The EEG showed moderate to severe
diffuse slowing and generalized rhythmic delta activity.
Table 3 The common neurological symptoms among participants
Neurological symptoms Total Disease severity Death outcome P-




Smell and taste dysfunctions 561 (64.3) 389 (67.8) 172 (57.5) 0.00 496 (66.0) 65 (53.3) 0.00
Myalgia 217 (24.9) 142 (24.7) 75 (25.1) 0.93 190 (25.3) 27 (22.1) 0.50
Headaches 110 (12.6) 86 (15.0) 24 (8.0) 0.00 104 (13.8) 6 (4.9) 0.00
Dizziness 104 (11.9) 75 (13.1) 29 (9.7) 0.16 94 (12.5) 10 (8.2) 0.37
Categorical variables are presented as numbers (percentages)
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Anosmia: 0.64 (0.48 to 0.85)
Headache: 0.49 (0.30 to 0.79)
Myalgia: 0.84 (0.60 to 1.18)
Dizziness: 0.72 (0.46 to 1.12)




Anosmia: 0.69 (0.52 to 0.94)
Headache: 0.52 (0.32 to 0.85)
Myalgia: 1.00 (0.71 to 1.40)
Dizziness: 0.68 (0.43 to 1.09)




Anosmia: 0.58 (0.39 to 0.86)
Headache: 0.32 (0.13 to 0.75)
Myalgia: 0.83 (0.53 to 1.32)
Dizziness: 0.72 (0.38 to 1.36)




Anosmia: 0.63 (0.39 to 0.95)
Headache: 0.37 (0.75 to 0.92)
Myalgia: 0.87 (0.52 to 1.43)
Dizziness: 0.62 (0.30 to 1.25)
Fig. 2 The prediction of severity and death due to COVID-19 by neurological manifestations









Days from first symptom to
event
Death





18 Female No ICH Left putamen hemorrhage 4 11 Yes
63 Male Yes Ischemic
stroke
Left Middle cerebral artery
plaque
24 13 Yes
65 Male Yes Ischemic
stroke
Left Middle cerebral artery
plaque
15 8 No
83 Female Yes ICH Right thalamus hemorrhage 3 8 Yes
72 Male Yes Ischemic
stroke
Right Middle cerebral artery
plaque
9 7 No
85 Male Yes Ischemic
stroke
Left Middle cerebral artery
plaque
23 8 Yes
38 Female Yes ICH Left putamen hemorrhage 4 13 Yes
68 Female Yes Ischemic
stroke
Right Middle cerebral artery
plaque
17 12 Yes
67 Male No Ischemic
stroke
Right Middle cerebral artery
plaque
10 16 No
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She was intubated and received intravenous levetirace-
tam (3000 mg) and generalized tonic-clonic seizure oc-
curred within 2 h of drug administration. Intravenous
midazolam was, then, added. No other convulsive sei-
zures were developed during hospitalization. Bilateral
ground glass opacities were observed in chest CT and
the RT-PCR test for COVID-19 was positive. Cerebro-
spinal (CSF) analysis showed clear appearance with no
cells, protein: 79 mg/dl (normal: 15–45), glucose: 135
mg/dl (normal: 45–80), and opening pressure: 22
cmH2O (normal: 6–25). The PCR panel of CSF was
negative for herpes simplex and no bacterial or fungal
organisms were detected. Other laboratory data showed
thrombocytopenia (n = 43,000) at the time of admission
but other tests were in normal limits (leukocytes: 5.1 ×
103/μL, Na: 142, K: 4.4, Ca: 9.4, Albumin: 3.4, and Mg:
2.1). Urine toxicology analysis for methanol, methadone,
benzodiazepines, cannabinoids, methamphetamine,
tramadol, and opiates were negative. The primary brain
CT scans showed no specific abnormalities but the top
of basilar infarction was observed after ten days of
hospitalization (Fig. 3 a, b). The patient died 16 days
after admission.
Follow-up
There were 442 individuals with hyposmia/anosmia and
dysgeusia who survived from COVID-19 and completed
the study. It was found that after 4 weeks of discharge,
209 cases (47.3%) fully recovered from these conditions;
181 cases (40.9%) had partial improvements; and 52
cases (11.8%) reported no changes in their smell and
taste dysfunctions. The full recovery was reported in 302
individuals (68.3%) after 8 weeks of discharge and partial
improvements were found among 119 participants
(26.9%). Twenty one cases (4.8%) with hyposmia (n = 15)
and anosmia (n = 6) reported no changes (Fig. 4). Inter-
mittent parosmia (distortion of odor perception when an
odor is present) was reported in 42 cases (9.5%) after 4
weeks and 137 cases (30.9%) after 8 weeks of discharge.
Intermittent phantosmia (odor perception in the absence
of odor stimulus) was also reported in 11 cases (2.5%)
after 4 weeks and 40 cases (9.0%) after 8 weeks of dis-
charge (Fig. 4). These events occurred in 86 cases
(48.6%) with recovered hyposmia/anosmia, 83 cases
(46.9%) with partial improvements, and eight case (4.5%)
with no smell and taste improvements.
Headaches were reported among 37 of 689 individuals
after 4 weeks of discharge (5.3%) (28 cases with
migraine-like and 9 cases with tension-like headaches)
and 14 cases (2.0%) after 8 weeks (11 cases with
migraine-like and 3 cases with tension-like headaches).
These individuals had no prior history of headaches (e.g.
migraine). The severity was mild to moderate and head-
aches were well-controlled with simple analgesics. No
functional impairments were reported among affected
individuals due to headaches. There were 21 participants
(3.0%) after 4 weeks and 9 cases (1.3%) after 8 weeks of
discharge with myalgia. Dizziness was also reported
among 9 individuals after 4 weeks that was recovered
after 8 weeks of discharge (Fig. 4).
The follow-up was continued in participants with par-
osmia, phantosmia, no improvements in smell and taste,
headaches, and myalgia (Fig. 4). The full recovery was
reported in 9 cases (6.6%) with parosmia, 3 cases (5.0%)
with phantosmia, 2 cases (9.5%) with no prior changes
in smell and taste sensations, 9 cases (64.3%) with head-
aches, and 4 cases with myalgia (44.4%) after 8 further
weeks of follow-up (16 weeks after discharge). Partial im-
provements were reported in 64 cases (46.7%) with par-
osmia, 12 cases with phantosmia (30.0%), and 7 cases
(33.3%) with no prior changes in smell and taste sensa-
tions after 16 weeks of discharge. The remaining cases
with headaches had mild migraine-like episodes.
Demyelinating myelitis
One 43-year-old-male visited Loghman hospital after 16
days of prior admission with weakness, paresthesia, and
paresis of upper and lower limbs. The patient also devel-
oped low abdominal pain with urinary retention. No his-
tory of similar symptoms and neurological disorders
were reported. The initial manifestations due to
COVID-19 were fever, fatigue, myalgia, and headaches
that were recovered after discharge. Neurological exami-
nations showed reduced forces of upper (4 / 5) and
lower limbs (2 / 5). The deep tendon reflexes of all ex-
tremities were normal (1+) and Babinski’s sign was
present. The position, vibration, and light tough sensa-
tions were impaired in lower limbs. The laboratory data
including leukocyte count, CRP, and LDH were normal.
The CSF analysis showed clear appearance with no cells,
protein: 60 mg/dl, glucose: 43 mg/dl, and opening pres-
sure: 18 cmH2O. The PCR panel of CSF was negative for
herpes simplex and no bacterial or fungal organisms
were detected. The CSF was assessed to detect anti-N-
methyl-D-aspartate (NMDA) antibody, oligoclonal band,
aquaporin-4 receptor (AQP-4), and myelin oligodendro-
cyte glycoprotein (MOG) antibodies which were nega-
tive. Serological testing for the anti-nuclear antibody,
anti-phospholipid antibodies, neuromyelitis optica, anti-
NMDA, AQP-4, and MOG antibodies was also negative.
The brain and spinal cord MRI showed bilateral thal-
amic hypersignal lesions (Fig. 3c) with longitudinally ex-
tensive transverse myelitis at cervical and thoracic cord
levels (Fig. 3 d, e). The patient was diagnosed with post-
infectious demyelinating myelitis and managed with
intravenous immunoglobulin (IVIG) for 7 days. Our pa-
tient was discharged from hospital after 16 days with
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significant improvements in forces of upper (5 / 5) and
lower limbs (4 / 5).
Guillain-Barré syndrome (GBS)
A 46-year-old-female visited Imam Hossein hospital
after 21 days of prior admission with weakness and
paresthesia of upper and lower limbs as well as bilateral
facial paralysis. The initial symptoms due to COVID-19
were fever and dry cough that were recovered after dis-
charge. Neurological examination showed decreased
forces of upper (4 / 5) and lower limbs (3 / 5) with mild
bilateral peripheral facial nerve palsy. The deep tendon
reflexes of all extremities were absent. The CSF analysis
showed no cells, protein: 93 mg/dl, glucose: 15 mg/dl,
and opening pressure: 18 cmH2O. The EMG-NCV was
conducted and acute axonal motor neuropathy (AMAN)
variant of GBS was diagnosed. The motor nerve conduc-
tion and F-wave response were measured on the median,
ulnar, tibial, and peroneal nerves. The sensory nerve
conduction was measured using median, ulnar, and sural
nerves. The normal NCV without evidence of conduc-
tion block, and normal sensory nerve action potential
(SNAP) amplitude along with reduced compound
muscle action potential (CMAP) amplitude were found
in both upper and lower extremities. The electromyo-
graphic findings were reduced voluntary recruitment
and increased insertional activity. The patient was
treated with five consequent days of IVIG but the
Fig. 3 Brain imaging of individuals with status epilepticus (a, b) and demyelinating myelitis (c, d, e)
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disease progressed and she developed dyspnea and was
intubated. Arrhythmia due to autonomic dysfunction
was also developed and pacemaker was inserted. The
IVIG was used for further 7 days. The symptoms im-
proved gradually and the patient was discharged after
42 days of hospitalizations with improvements in forces
of lower limbs (4 / 5).
Discussion
The COVID-19 is the third outbreak of coronaviruses
after SARS and MERS, which occurred in 2002 and
2012; respectively. The SARS and MERS diseases led to
less than 2000 deaths but the current pandemic out-
break of COVID-19 has claimed more than one million
lives in less than a year. All three viruses were found to
involve vital organ systems including nervous system
[22–24]. The incidence of neurological manifestations
was assessed in our study among hospitalized individuals
with positive RT-PCR of SARS-CoV-2. The smell and
taste dysfunctions were the third most common symp-
toms in our cases after fever and cough. It was identified
that about two-third of our participants experienced
smell and taste dysfunctions that resolved partially or
completely in 98% of cases after 16 weeks of discharge
from hospital. Myalgia (25%), headaches (13%), dizziness
(12%), and cerebrovascular events (1%) were also re-
ported in participants. Three individuals presented status
epilepticus, post-infectious demyelinating myelitis, and
AMAN variant of GBS.
The involvement of nervous system in COVID-19 dis-
ease can be attributed to the direct invasion of virus or
secondary para-infectious mechanisms. The SARS-CoV-
2 was found to enter the human cells using angiotensin
converting enzyme 2 (ACE2) receptors [25] that can be
expressed on nasal goblet and ciliated epithelial cells as
well as oligodendrocytes [26, 27]. The detection of the
SARS-CoV-2 in the CSF of cases with encephalopathy
[28, 29] and demyelinating disorder [30] was an import-
ant clue to show that the virus could be neuroinvasive.
Furthermore, viral particles were found in the brain tis-
sue of cases with the COVID-19 disease [31, 32]. It
should be noted that these results should be interpreted
with caution [33]. Small numbers of cases were identi-
fied and some studies reported no evidence of the
SARS-CoV-2 detection in the CSF or brain tissue of
confirmed COVID-19 cases with neurological symptoms
[34, 35]. The hyper-inflammatory state due to over-
production of cytokines (e.g. interleukin-6 and tumor
necrosis factor) also known as “cytokine storm” was re-
ported to be another plausible underlying mechanism of
neuronal damage in COVID-19 disease [36].
Several studies reported that hyposmia/ anosmia and
dysgeusia were about 20 to 98% prevalent among con-
firmed cases with COVID-19 [7, 8, 37–39]. The discrep-
ancies in results can be due to the methodological
differences. The study design, sample size, recruitment
setting (inpatients vs. outpatients), and model of testing
smell sensation (self-reporting survey vs. physical exam)
could significantly affect the results. It was found that
anosmia was more common in non-hospitalized individ-
uals than hospitalized ones with COVID-19 [40, 41].
Our study showed that loss of smell and taste was asso-
ciated with reduced odds of severe cases and death due
among hospitalized cases. A recent study on 576 inpa-
tients also demonstrated that cases with anosmia had
lower mortality rate and less severe course of the disease
[42]. The follow-up of individuals with the COVID-19
and hyposmia/ anosmia was assessed in few studies. An
observational cohort study reported that over 70% of
cases with smell and taste dysfunctions had early
Fig. 4 Number of participants with neurological symptoms during follow-up
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improvements after 4 weeks of onset of anosmia [43].
The recovery in all cases was reported in another study
in 28 days [44]. A 6-month follow-up study on 434 indi-
viduals showed that over 70% had full or almost full re-
covery of loss of smell and about 2% of cases reported
no improvements [45]. It was also reported that over
40% of participants developed parosmia with the median
interval of 2.5 months after the onset of smell dysfunc-
tion [45]. Our study also showed that about 10% of cases
with hyposmia/anosmia developed parosmia after 4
weeks of discharge that increased to over 30% after 8
weeks. Longer follow-up periods are needed to assess
the prognosis of altered smell functions.
A systematic literature review estimated that myalgia
(28.5%) and headaches (14%) were common manifesta-
tions of COVID-19 [46]. In consistent with this study, it
was previously found that headaches were independent
predictors of lower risk of mortality among hospitalized
cases [47]. We found that migraine-like episodes were
the most frequent phenotype of headaches among the
participants. A recent study also showed that headaches
were common manifestations in COVID-19 and they
were mostly presented as bilateral severe headaches at
the time of admission with migraine phenotype [48] In-
dividuals who diagnosed with COVID-19 were found to
be at 0.5 to 1.3% risk of subsequent cerebrovascular
events including ischemic stroke, ICH, and cerebral ven-
ous thrombosis [10, 49]. It was reported that among in-
dividuals with COVID-19 and stroke, older age, higher
baseline NIHSS, and cryptogenic stroke were associated
with early mortality [50].
To date, few cases with post-infectious demyelinating
conditions of the central nervous system (CNS) after the
COVID-19 disease were diagnosed [13, 51]. The struc-
ture and replication of SARS-CoV-2 was reported to be
similar with mouse hepatitis virus (MHV) [52]. The
MHV was found to remain in mouse CNS after acute in-
fection and could induce an immune-mediated, chronic
demyelinating disease, similar to multiple sclerosis in
humans [33, 53]. We found two individuals with the
CNS demyelination in our medical centers (51, present
study) during COVID-19 pandemic outbreak. Future
longitudinal studies should assess the prevalence of these
events in confirmed COVID-19 cases. The post-
infectious demyelination of peripheral nervous system
was also reported after recovery from COVID-19 dis-
ease. The GBS is a relatively rare disease with the inci-
dence ranged from 0.81 to 1.89 per 100,000 person-years
[54]. Of 873 hospitalized individuals in our study, one
case developed AMAN variant of GBS. Another study
with 1200 patients also reported the incidence of 0.4%
for GBS [55]. Systematic review studies reported that the
majority of cases with COVID-19 and GBS had acute in-
flammatory demyelinating polyradiculopolyneuropathy
(AIDP) variant [56, 57]. The facial nerve palsy that was
observed in our participant was also found in about half
of the prior reported cases [56].
To our knowledge, this was the first multi-center pro-
spective study assessed the course of different neuro-
logical manifestations associated with COVID-19
disease. The prospective design of the study could re-
duce the possible information bias. The study was also
multi-center that can increase the external validity.
There were some limitations to our study. Some symp-
toms including anosmia and dysgeusia are often under-
reported by patients with severe disease and our results
could be affected by this measurement bias. Participants
were sampled from hospitals rather than community
(hospital based vs. population based studies). This can
lead to selection bias (Berkson’s bias); as many individ-
uals with mild severity were not included in our study.
A short period of follow-up and lacking control group
were other major limitations that should be resolved in
future studies. Some neurological symptoms (e.g. smell
and taste sensations, headaches, and myalgia) were not
objectively assessed and were reliant on individuals’ re-
ports. Further studies should be conducted to assess the
incidence of CNS demyelinating events and evaluate the
course of altered smell sensation including parosmia and
phantosmia.
Conclusions
Neurological symptoms are prevalent among individuals
with the COVID-19 and should not be under-estimated
during the current pandemic outbreak. The smell and
taste dysfunctions and headaches were common neuro-
logical symptoms that were associated with less severe
cases and lower mortality rates.
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